Toxoplasmosis is an infectious disease caused by protozoan parasite Toxoplasma gondii, one of the world’s most dreaded parasite. There are 3 major genotypes of Toxoplasma gondii, namely (type 1, type 2, and type 3). These genotypes differ in their pathogenicity and prevalence among people around the world. Toxoplasmosis may be caused by transmission of T.gondii parasite through open wounds, consumption of contaminated raw meat, mutton, pork, beef, or by transfusion of blood, and organ transplant. Healthy people usually exhibit flu like symptoms such as fever, fatigue, swollen lymph nodes, and headaches. People with a weak immune system augmented by conditions such as HIV/AIDS, are more likely to develop severe infections form the parasite. Toxoplasmosis can transmit transplacentally from mother to fetus if the mother becomes infected with toxoplasmosis during or just before pregnancy. The above mentioned condition may result into a miscarriage, a stillborn child, or with symptoms of toxoplasmosis. Diagnosis of Toxoplasmosis can be established by toxoplasmosis serologic profile (TSP) tests which include dye test (gold standard), indirect immune fluorescent test (IFAT), modified agglutination test (MAT), enzyme-linked immunosorbent assay (ELISA),immunoglobulin tests (IgG, IgM, and IgE antibodies tests). Other test comes under TSP test includes amplification of specific nucleic acid sequences (i.e. PCR), histological diagnosis, and isolation of T.gondii parasite. In infant diagnosis can be performed by procedures such as amniocentesis, and ultrasound scan. Diagnosis can also be made by direct observation of the parasite in stained tissue sections, cerebrospinal fluids (CSF), and blood, but these procedures are less frequently used because of difficulty in obtaining samples.
Read the Comprehensive Overview of Toxoplasmosis Diagnostic Testing Market: http://www.transparencymarketresearch.com/toxoplasmosis-diagnostic-testing-market.html
Geographically toxoplasmosis diagnostic testing market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Currently North America dominates the toxoplasmosis diagnostic testing market, followed by Europe. In the U.S. and Europe, type 2 genotype is more prevalent among people than the other two species. Rising incidences of chronic diseases, along with major consumption of meat, pork, beef, and mutton, has resulted in increasing demand for effective testing methods for T.gondii by diagnostics laboratories in these regions. Technological advancement would also boost the market demand for Toxoplasmosis diagnostic testing in the North America and Europe. By 2018, Asia Pacific region is expected to grow at fastest rate, owing to the large population base in the region, increasing incidences of chronic diseases, rising demand for technologically advanced diagnostic devices, region’s growing healthcare infrastructure, combined with government initiatives in providing better healthcare facilities.
Technological advancements in toxoplasmosis diagnostic testing such as touch down-multiplex PCR, increasing number of anti-infective drugs, and improving healthcare infrastructure around the world are some of the key drivers for the growth of toxoplasmosis diagnostic testing market. However, high cost of toxoplasmosis tests, and lack of awareness about the parasitic infection are some of the restraints in toxoplasmosis diagnostic testing market growth. Improving safety and quality of toxoplasmosis diagnostic devices, improving healthc artte infrastructure focus on the emerging markets (China and India), and providing low cost devices, would act as a new opportunities for players in the global toxoplasmosis diagnostic testing market. On the basis of end – users, the toxoplasmosis diagnostic testing market has been segmented into hospitals, pathology laboratories, clinics, and diagnostic centers.
Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14327
The major players in toxoplasmosis diagnostic testing market are Abbott Laboratories, Bio-Rad Laboratories, Inc. Affymetrix, Inc., and Beckman Coulter, Inc. Other players having presence in the toxoplasmosis diagnostic testing market includes Biotest Biomerica, Inc., Cepheid, Inc., and GenBio.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453